A statistical reanalysis of the pivotal Alzheimer's trials for lecanemab and donanemab has found that both drugs' effect on cognitive decline reversed direction once the double-blind phase ended and patients entered open-label extensions, with decline rates in the extensions approaching those seen in the original placebo groups. The analysis, published August 10 in BMJ Neurology Open, re-examined published trial data rather than collecting new patient records, and its authors say the pattern undercuts the extension studies that manufacturers have cited as evidence of growing long-term benefit.
Lecanemab (Clarity AD) and donanemab (TRAILBLAZER-ALZ 2) were each tested over an 18-month, double-blind, placebo-controlled phase before regulators approved them for early Alzheimer's disease; both trials reported modest slowing of decline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale versus placebo. Afterward, participants could enter open-label extensions in which everyone received active drug. Eisai and Eli Lilly, the two manufacturers, have reported those extensions show continuing or growing benefit, comparisons made against historical, untreated registry cohorts such as the Alzheimer's Disease Neuroimaging Initiative, not against a concurrent placebo group. The new paper, led by Alok K. Dwivedi of the University of Missouri and Alberto J. Espay of the University of Cincinnati, instead compared each trial's double-blind and open-label decline rates against each other and against simulations built from the trials' own published means, variances and dropout patterns.
Among participants who received lecanemab from the start, the researchers calculated that the annualized rate of CDR-SB decline rose from 0.78 points a year during the double-blind phase to 1.30 points a year during the extension, a difference of 0.53 points (95% confidence interval, 0.40 to 0.66; p less than 0.001). Donanemab's early-start group showed a comparable rise, from 1.07 to 1.73 points a year, a difference of 0.66 (95% CI, 0.41 to 0.91; p less than 0.001). Participants who had been on placebo during the blinded phase and then switched to active drug showed no meaningful change in decline rate once they, too, entered the open-label period. The steeper extension-phase decline occurred even though 40 to 45 percent of participants had already dropped out before the extensions ended, an attrition pattern that should have left the remaining group skewed toward slower progressors, the authors noted.
The finding does not show that either drug caused faster decline once blinding lifted; the paper is a secondary, simulation-based reanalysis of previously published summary statistics rather than a new trial with patient-level data, and it cannot rule out that unblinding itself, changes in expectations, or standard disease progression after longer follow-up explain the shift. Eisai's own delayed-start comparisons, cited in the paper, had separately shown lecanemab-treated and placebo-crossover trajectories converging by 36 months rather than separating further, a pattern the authors describe as inconsistent with a growing disease-modifying effect; a similar pattern has been reported for donanemab's delayed-start data.